Company Presentation • 15 Apr 2025 19:00
Company Presentation • 21 May 2025 19:00
Company Presentation • 09 Jan 2025 20:00
Company Presentation • 02 Dec 2024 20:00
No more presentations
Search or
𝛼SK
𝛼SKENTITY
MetaVia (MTVA US)
MetaVia (MTVA US)
14
Analysis
Health Care • United States
MetaVia Inc. operates as a clinical-stage biotechnology company. The Company focuses on developing dual oxyntomodulin (OXM) analog agonist for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). MetaVia serves customers worldwide.
morex